placebo Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI

A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma

A PHASE III RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL TO EVALUATE EFFICACY AND SAFETY OF TIOTROPIUM INHALATION SOLUTION DELIVERED VIA RESPIMAT® INHALER (2,5 Y 5 µg ONCE DAILY) COMPARED WITH PLACEBO AND SALMETEROL HFA MDI (50 µG DOS VECES POR DIA) OVER 24 WEEKS IN PATIENTS WITH MODERATE PERSISTENT ASTHMA